It was found that after silencing CERS6-AS1, the proliferation, clone formation, and migration of DU145 cells were inhibited, but the apoptosis rate increased, which was consistent with the anticancer effect of knockdown CERS6-AS1 reported by Yun et al. These findings suggest that CERS6-AS1 plays an oncogene role in prostate cancer, and silencing CERS6-AS1 may be a potential treatment strategy for prostate cancer. Here, CERS6 is linked to prostate cancer.